Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

C. Turner, Nicholas; Oliveira, Mafalda; J. Howell, Sacha; Dalenc, Florence; Cortés, Javier; Gómez, Henry; Hu, Xichun; Jhaveri, Komal; Krivorotko, Petr; Loibl, Sibylle; Morales Murillo, Serafin; Okera, Meena; Hee Park, Yeon; Sohn, Joohyuk; Toi, Masakazu; Tokunaga, Eriko; Yousef, Samih; Zhukova, Lyudmila; C. de Bruin, Elza; Grinsted, Lynda; Schiavon, Gaia; Foxley, Andrew; S. Rugo, Hope

doi:10.1056/nejmoa2214131

Public

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

Published in New England Journal of Medicine • May 31, 2023

Authors:

Nicholas C. Turner

Mafalda Oliveira

Sacha J. Howell

Abstract

AKT pathway activation is implicated in endocrine-therapy resistance. Data on the efficacy and safety of the AKT inhibitor capivasertib, as an addition to fulvestrant therapy, in patients with hormone receptor–positive advanced breast cancer are limited. Download a PDF of the Research Summary. In a ...

Subject

Fulvestrant

Breast cancer

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!